Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC74462ZimberelimabCAS: 2259860-24-5纯度: >99.00%
Zimberelimab(GLS-010)是一种完全人IgG4抗PD-1单克隆抗体,对人PD-1的EC50为210pM。
- GC74467CemiplimabCAS: 1801342-60-8纯度: >99.00%
Cemiplimab(抗人PD-1)是一种高亲和力程序性死亡受体-1(PD-1)单克隆IgG4抗体,可阻断PD-1/PD-L1介导的T细胞抑制。
- GC74472ConatumumabCAS: 896731-82-1纯度: >98.00%
Conatumumab(AMG 655)是针对人死亡受体5(DR5,TRAILR2)的人单克隆激动剂抗体(Kd:1nM的长形式DR5,0.8nM的短形式DR5)。
- GC74486LexatumumabCAS: 845816-02-6纯度: >96.00%
Lexatumumab(HGS-ETR 2)是一种人激动性TRAIL受体2(TRAIL-R2、DR5、APO-2)IgG4κ型单克隆抗体。
- GC74501AdebrelimabCAS: 2247114-85-6纯度: >97.00%
Adebrelimab(SHR-1316)是一种人源化IgG4单克隆PD-L1(PD-1/PD-L1)抗体。
- GC74532TuvonralimabCAS: 2417649-44-4纯度: >99.00%
Tuvonralimab (psb - 205;QL1706)是一种双免疫检查点阻断剂,含有抗pd -1 IgG4和抗ctla -4 IgG1抗体的混合物,Iparomlimab和Tuvonralimab。
- GC74542Cinrebafusp alfaCAS: 2218515-90-1纯度: >98.00%
Cinrebafusp alfa(PRS 343)是一种高亲和力CD137/HER2双特异性抗毒蛋白药物。
- GC74543EzabenlimabCAS: 2249882-54-8纯度: >99.00%
Ezabenlimab (BI-754091)是一种抗pd -1单抗,结合常数Kd值为6 nM (CHO细胞)。
- GC74553GeptanolimabCAS: 2348469-43-0纯度: >97.00%
Geptanolimab(CBT-501)是一种针对程序性死亡-1(PD-1)的人源化IgG4k单克隆抗体。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC74449 | Vonsetamig | 2408319-33-3 | >95.00% | |
Vonsetamig是一种人源免疫球蛋白G4-kappa,抗tnfrsf17和CD3E单克隆抗体。 | ||||
| GC74460 | Visugromab | 2556646-63-8 | >98.00% | |
Visugromab (CTL-002)是一种GDF-15中和IgG4单抗。 | ||||
| GC74462 | Zimberelimab | 2259860-24-5 | >99.00% | |
Zimberelimab(GLS-010)是一种完全人IgG4抗PD-1单克隆抗体,对人PD-1的EC50为210pM。 | ||||
| GC74464 | Cadonilimab | 2394841-59-7 | >99.00% | |
Cadonilimab(AK104)是一种靶向PD1/CTLA4的人源化四价IgG1双特异性抗体。 | ||||
| GC74467 | Cemiplimab | 1801342-60-8 | >99.00% | |
Cemiplimab(抗人PD-1)是一种高亲和力程序性死亡受体-1(PD-1)单克隆IgG4抗体,可阻断PD-1/PD-L1介导的T细胞抑制。 | ||||
| GC74469 | Tabalumab | 1143503-67-6 | >98.00% | |
Tabalumab (LY2127399)是一种人抗BAFF (b细胞活化因子)单克隆抗体(IgG4型),具有中和膜结合和可溶性BAFF的活性。 | ||||
| GC74472 | Conatumumab | 896731-82-1 | >98.00% | |
Conatumumab(AMG 655)是针对人死亡受体5(DR5,TRAILR2)的人单克隆激动剂抗体(Kd:1nM的长形式DR5,0.8nM的短形式DR5)。 | ||||
| GC74476 | Seribantumab | 1334296-12-6 | >95.00% | |
Seribantumab (MM 121)是一种靶向HER3的全人源IgG2单克隆抗体。 | ||||
| GC74477 | Tigatuzumab | 918127-53-4 | >95.00% | |
Tigatuzumab(CS-1008)是一种靶向死亡受体5(DR5)的人源化IgG1单克隆抗体。 | ||||
| GC74482 | Drozitumab | 912628-39-8 | >99.00% | |
Drozitumab(PRO 95780)是一种结合死亡受体DR5的人激动性单克隆抗体。 | ||||
| GC74486 | Lexatumumab | 845816-02-6 | >96.00% | |
Lexatumumab(HGS-ETR 2)是一种人激动性TRAIL受体2(TRAIL-R2、DR5、APO-2)IgG4κ型单克隆抗体。 | ||||
| GC74500 | Acasunlimab | 2253937-12-9 | >99.00% | |
Acasunlimab (GEN1046)是针对PD-L1和4-1BB的双特异性抗体(bsAb)。 | ||||
| GC74501 | Adebrelimab | 2247114-85-6 | >97.00% | |
Adebrelimab(SHR-1316)是一种人源化IgG4单克隆PD-L1(PD-1/PD-L1)抗体。 | ||||
| GC74507 | Asunercept | 1450882-18-4 | >98.00% | |
Asunercept (APG101;CAN008)是一种靶向CD95L的可溶性CD95-Fc融合蛋白。 | ||||
| GC74515 | Benufutamab | 2109730-69-8 | >98.00% | |
Benufutamab(GEN1029)是一种死亡受体5(DR5)特异性激动抗体。 | ||||
| GC74532 | Tuvonralimab | 2417649-44-4 | >99.00% | |
Tuvonralimab (psb - 205;QL1706)是一种双免疫检查点阻断剂,含有抗pd -1 IgG4和抗ctla -4 IgG1抗体的混合物,Iparomlimab和Tuvonralimab。 | ||||
| GC74534 | Tagitanlimab | 2417649-97-7 | >99.00% | |
Tagitanlimab (HBM-9167)是一种人源抗pd - l1抗体(IgG1κ型)。 | ||||
| GC74538 | Sotevtamab | 2411526-47-9 | >99.00% | |
Sotevtamab (16B5)是一种人源IgG2抗聚簇素单克隆抗体(mAb)。 | ||||
| GC74541 | Socazolimab | 2305043-30-3 | >98.00% | |
Socazolimab(ZKAB001)是一种抗PD-L1单克隆抗体。 | ||||
| GC74542 | Cinrebafusp alfa | 2218515-90-1 | >98.00% | |
Cinrebafusp alfa(PRS 343)是一种高亲和力CD137/HER2双特异性抗毒蛋白药物。 | ||||
| GC74543 | Ezabenlimab | 2249882-54-8 | >99.00% | |
Ezabenlimab (BI-754091)是一种抗pd -1单抗,结合常数Kd值为6 nM (CHO细胞)。 | ||||
| GC74553 | Geptanolimab | 2348469-43-0 | >97.00% | |
Geptanolimab(CBT-501)是一种针对程序性死亡-1(PD-1)的人源化IgG4k单克隆抗体。 | ||||
| GC74556 | Gilvetmab | 1808081-43-7 | >99.00% | |
Gilvetmab是一种有效的犬化抗pd -1单克隆抗体。Gilvetmab阻断PD-1与其配体PDL-1的相互作用。 | ||||
| GC74560 | Inezetamab | 2568264-76-4 | >99.00% | |
Inezetamab是一种双特异性抗CD40和抗MSLN IgG1单克隆抗体。 | ||||
